A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir
Status:
Completed
Trial end date:
1999-08-01
Target enrollment:
Participant gender:
Summary
To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16
weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm.
While indinavir is currently the most commonly prescribed protease inhibitor, the optimal
therapy for a person on an indinavir-containing regimen who experiences a rebound in viral
load or never experiences a decrease in viral load below 500 copies per milliliter is
unknown. Current clinical practice for such patients typically involves empiric use of a
combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and
at least 1 other antiretroviral agent to which the patient has had little or no prior
exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or
nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally
evaluate some of these options in indinavir-experienced patients.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)